Intravitreal Bevacizumab for the Treatment of Non-arteritic Anterior Ischemic Optic Neuropathy

1. Chung Hyun Lee
2. Sae Woon Sohn
3. Sung Jae Yang

Gangneung Asan Hospital, College of medicine, University of Ulsan, Gangneung-si, Korea

Purpose: To present the effect of intravitreal bavacizumab injection for the treatment of Non-arteritic anterior ischemic optic neuropathy.

Methods: Retrospectively reviewed the medical records of 2 consecutive patients who treated with intravitreal injection of bevacizumab for the treatment of Non-arteritic anterior ischemic optic neuropathy.

Results: Patient one was a 64-year-old woman with Non-arteritic Anterior Ischemic Optic Neuropathy, her vision of right eye was 0.05. Three weeks after intravitreal injection of bevacizumab, vision impoved to 0.16.

Patient two was a 57-year-old man with Non-arteritic Anterior Ischemic Optic Neuropathy, his vision of right eye was 0.4. 2 weeks after intravitreal injection of bevacizumab, vision impoved to 0.63.

There were resolution of disc swelling and/or leakage from fluorescein angiography within 2~6 weeks in all two cases. There was no injection related complication.

Conclusions: The visual acuity of all the three patients improved within few weeks. Intravitreal bevacizumab injection for the treatment of Non-arteritic anterior ischemic optic neuropathy seems effective and safe. And intravitreal bevacizumab injection can be one of options for the treatment of Non-arteritic anterior ischemic optic neuropathy and shortened the duration of symptom.